BR0211130A - Plantas transgênicas que expressam proteìnas de ligação da cobalamina - Google Patents

Plantas transgênicas que expressam proteìnas de ligação da cobalamina

Info

Publication number
BR0211130A
BR0211130A BR0211130-6A BR0211130A BR0211130A BR 0211130 A BR0211130 A BR 0211130A BR 0211130 A BR0211130 A BR 0211130A BR 0211130 A BR0211130 A BR 0211130A
Authority
BR
Brazil
Prior art keywords
binding proteins
transgenic plants
vitamin
plants expressing
cobalamin binding
Prior art date
Application number
BR0211130-6A
Other languages
English (en)
Inventor
Lars Erick Berglund
Torben Ellebaek Petersen
Sergey Nikolaevich Fedosov
Ebba Nexo
Niels Bech Laursen
Erik Ostergaard Jensen
Original Assignee
Cobento Biotech Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cobento Biotech Aps filed Critical Cobento Biotech Aps
Publication of BR0211130A publication Critical patent/BR0211130A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
    • A01H1/00—Processes for modifying genotypes ; Plants characterised by associated natural traits
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Developmental Biology & Embryology (AREA)
  • Environmental Sciences (AREA)

Abstract

"PLANTAS TRANSGêNICAS QUE EXPRESSAM PROTEìNAS DE LIGAçãO DA COBALAMINA". A presente invenção está relacionada com o uso de plantas transgênicas para a expressão das proteínas de ligação da vitamina B12 (cobalamina) . As células da planta são transformadas com seq³ências de nucleotídeos adaptadas para expressão e secreção das proteínas de ligação da vitamina B12. A presente invenção está relacionada também com o uso de proteínas de ligação da vitamina B12 recombinante de plantas em testes analíticos e tratamento de deficiência de vitamina B12. Também é apresentado um método para purificação de proteínas de ligação da vitamina B12 recombinante.
BR0211130-6A 2001-07-13 2002-07-12 Plantas transgênicas que expressam proteìnas de ligação da cobalamina BR0211130A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0117171A GB2377446B (en) 2001-07-13 2001-07-13 Expression of cobalamin binding proteins in transgenic plants
PCT/GB2002/003227 WO2003006661A2 (en) 2001-07-13 2002-07-12 Transgenic plants expressing cobalamin binding proteins

Publications (1)

Publication Number Publication Date
BR0211130A true BR0211130A (pt) 2004-10-26

Family

ID=9918480

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0211130-6A BR0211130A (pt) 2001-07-13 2002-07-12 Plantas transgênicas que expressam proteìnas de ligação da cobalamina

Country Status (16)

Country Link
US (5) US20040268440A1 (pt)
EP (1) EP1417320A2 (pt)
JP (1) JP2004533851A (pt)
KR (1) KR20040027876A (pt)
CN (1) CN1549862A (pt)
BR (1) BR0211130A (pt)
CA (1) CA2453574A1 (pt)
EA (1) EA200400174A1 (pt)
GB (1) GB2377446B (pt)
HU (1) HUP0400458A3 (pt)
IL (1) IL159817A0 (pt)
MX (1) MXPA04000377A (pt)
NZ (1) NZ531026A (pt)
PL (1) PL367827A1 (pt)
WO (1) WO2003006661A2 (pt)
ZA (1) ZA200400751B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006010369A2 (en) * 2004-07-29 2006-02-02 Cobento A/S Methods for determining proteins and protein-bound compounds comprising enzymatic modification
US7790363B2 (en) 2005-02-07 2010-09-07 Abbott Laboratories Inc. Diagnostic test for vitamin B12
CA2955896A1 (en) * 2014-09-15 2016-03-24 Nestec S.A. Method for determining vitamin b12 uptake
WO2016187512A1 (en) 2015-05-20 2016-11-24 Syracuse University Compositions and methods for enhancing peptide stability against protease digestion
US20180154007A1 (en) * 2015-05-20 2018-06-07 Syracuse University Glycemic Control Using Intrinsic Factor Bound to A Vitamin B12 Conjugate of a Glucagon-Like Peptide-1 Receptor Agonist
WO2020236903A1 (en) * 2019-05-20 2020-11-26 Syracuse University Pharmaceutical formulations and methods for delivering a therapeutic, diagnostic, or imaging agent to cd206
CN114206367A (zh) * 2019-08-09 2022-03-18 美国西门子医学诊断股份有限公司 抗猪tcn1单克隆抗体及其生产和使用方法
WO2023089616A1 (en) * 2021-11-18 2023-05-25 Imagindairy Ltd. Food compositions comprising recombinant cells comprising transcobalamin

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3591678A (en) * 1969-09-05 1971-07-06 American Cyanamid Co Method of purifying intrinsic factor
US4279886A (en) * 1979-01-02 1981-07-21 University Patents, Inc. Test for pancreatic exocrine function
SU1751207A1 (ru) 1990-04-20 1992-07-30 Институт общей генетики им.Н.И.Вавилова Рекомбинантна плазмидна ДНК pST20, кодирующа альфа-интерферон человека в растени х табака
JPH0549478A (ja) * 1991-06-06 1993-03-02 Kanegafuchi Chem Ind Co Ltd ヒト内因子をコードするｄｎａ配列
US5548064A (en) * 1993-05-24 1996-08-20 Biotech Australia Pty Limited Vitamin B12 conjugates with EPO, analogues thereof and pharmaceutical compositions
US5939288A (en) * 1995-06-07 1999-08-17 Iowa State University Research Foundation, Inc. Plant secretory signal peptides and nectarins
US5959187A (en) * 1996-09-26 1999-09-28 Bailey; James E. Expression of oxygen-binding proteins in plants
CN100410268C (zh) * 1998-12-23 2008-08-13 博伊斯汤普生植物研究所 免疫原性的乙型肝炎表面抗原在转基因植物中的表达
DE60044858D1 (de) * 1999-10-26 2010-09-30 Stichting Dienst Landbouwkundi Säugetierartige Glykosylierung in Pflanzen
CN1301718A (zh) * 1999-12-27 2001-07-04 上海博德基因开发有限公司 一种新的多肽——钴胺素结合蛋白10和编码这种多肽的多核苷酸
WO2002064750A2 (en) * 2001-02-14 2002-08-22 Ventria Bioscience Expression system for seed proteins
DK1904636T3 (da) * 2005-07-12 2010-10-18 Greenovation Biotech Gmbh Forbedringer inden for eller i sammenhæng med proteinfremstilling

Also Published As

Publication number Publication date
IL159817A0 (en) 2004-06-20
HUP0400458A3 (en) 2005-06-28
CN1549862A (zh) 2004-11-24
US20150157731A1 (en) 2015-06-11
ZA200400751B (en) 2005-04-29
GB0117171D0 (en) 2001-09-05
NZ531026A (en) 2005-09-30
KR20040027876A (ko) 2004-04-01
PL367827A1 (en) 2005-03-07
US20100184642A1 (en) 2010-07-22
US20150158922A1 (en) 2015-06-11
GB2377446A (en) 2003-01-15
WO2003006661A3 (en) 2003-07-24
MXPA04000377A (es) 2005-03-07
EA200400174A1 (ru) 2005-06-30
CA2453574A1 (en) 2003-01-23
GB2377446B (en) 2005-06-29
US20040268440A1 (en) 2004-12-30
WO2003006661A2 (en) 2003-01-23
US9751918B2 (en) 2017-09-05
EP1417320A2 (en) 2004-05-12
US20150158920A1 (en) 2015-06-11
HUP0400458A2 (hu) 2004-11-29
JP2004533851A (ja) 2004-11-11

Similar Documents

Publication Publication Date Title
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
AR006188A1 (es) "composicion farmaceutica para inhibir la actividad de serinproteasa, metodo in vitro para inhibir la actividad de serinproteasa y metodo para preparar dicha composicion".
PT1049767E (pt) Coelho transgenico que expressa uma lipoproteina (a) humana funcional
BR0011499A (pt) Moléculas de ácido nucléico oriundas de plantas e células de,planta transgênicas de trigo e o seu uso para a produção de amido modificado
BRPI0407822A (pt) polinucleotìdeos e polipeptìdeos nas plantas
TR199802423T2 (xx) Konsantre antikor terkibi.
DE60140773D1 (de) Polypeptide zur Bindung an das B-Lymphozyten-stimulatorische Protein (BLyS)
TR200100056T2 (tr) Nörotrofik faktörler
ECSP045520A (es) Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos
BR9915152A (pt) Moléculas de ácido nucléico de arroz e o seu uso para a produção de amido modificado
BR0010318A (pt) ácidos nucléicos de fitil/prenil-transferase, polipeptìdeos e uso dos mesmos
EP0921818A4 (en) THERAPEUTIC AND DIAGNOSTIC METHODS AND COMPOSITIONS BASED ON JAGGED / NOTCH PROTEINS AND AMINO ACIDS
DE69942861D1 (de) Ldcam genannte moleküle
BR0114199A (pt) Sequências de nucleotìdeos que medeiam a fertilidade masculina e métodos de uso das mesmas
BRPI0416544A (pt) proteìna de ligação de gag
BR0211130A (pt) Plantas transgênicas que expressam proteìnas de ligação da cobalamina
ZA87141B (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors,biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
ES549115A0 (es) Procedimiento de producir preparaciones para tratar pacien- tes de hemofilia a inhibidores
Rubinoff et al. The isolation and characterization of the folate binding protein from goat milk
BR0114847A (pt) Sequências de ácido nucléico para proteìnas envolvidas em sìntese de tocoferol
PT1007559E (pt) Celulas geneticamente modificadas que expressam as proteinas morfogeneticas do osso
BR0305018A (pt) Células dendrìticas tolerogênicas e usos terapêuticos para as mesmas
ATE291586T1 (de) Humanes antibiotisches protein
DK1051491T3 (da) Equin Fc Epsilon receptor-alfa-kæde-nukleinsyremolekyler, korresponderende proteiner og anvendelse heraf
DK1165102T3 (da) Matrixproteinpræparater til podning i ikke-mineraliseret væv

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: COBENTO BIOTECH A/S (DK)

Free format text: ALTERADO DE: COBENTO BIOTECH APS

B25A Requested transfer of rights approved

Owner name: COBENTO A/S (DK)

Free format text: TRANSFERIDO DE: COBENTO BIOTECH A/S

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A E 9A A NUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2108 DE 31/05/2011.